458 related articles for article (PubMed ID: 15954437)
1. [CD20 antibody for the treatment of systemic autoimmune diseases].
Tanaka Y
Nihon Rinsho; 2005 May; 63 Suppl 5():728-33. PubMed ID: 15954437
[No Abstract] [Full Text] [Related]
2. [CD20 antibody for treatment of rheumatoid arthritis].
Tanaka Y
Nihon Rinsho; 2005 Jan; 63 Suppl 1():544-8. PubMed ID: 15799415
[No Abstract] [Full Text] [Related]
3. [New treatments for systemic diseases].
Bader-Meunier B; Willems M
Arch Pediatr; 2006 Jun; 13(6):596-8. PubMed ID: 16690273
[No Abstract] [Full Text] [Related]
4. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis.
Looney RJ
Rheumatology (Oxford); 2005 May; 44 Suppl 2():ii13-ii17. PubMed ID: 15851522
[TBL] [Abstract][Full Text] [Related]
5. Prospects for B-cell-targeted therapy in autoimmune disease.
Edwards JC; Cambridge G
Rheumatology (Oxford); 2005 Feb; 44(2):151-6. PubMed ID: 15509628
[No Abstract] [Full Text] [Related]
6. CD20-depleting therapy in autoimmune diseases: from basic research to the clinic.
Perosa F; Prete M; Racanelli V; Dammacco F
J Intern Med; 2010 Mar; 267(3):260-77. PubMed ID: 20201920
[TBL] [Abstract][Full Text] [Related]
7. B cell targeted therapies in autoimmune diseases.
Isenberg DA
J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
[TBL] [Abstract][Full Text] [Related]
8. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Hutas G
Curr Opin Investig Drugs; 2008 Nov; 9(11):1206-15. PubMed ID: 18951300
[TBL] [Abstract][Full Text] [Related]
9. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus.
Eisenberg R; Albert D
Nat Clin Pract Rheumatol; 2006 Jan; 2(1):20-7. PubMed ID: 16932648
[TBL] [Abstract][Full Text] [Related]
10. [Molecular targets and their regulation in systemic lupus erythematosus and lupus nephritis].
Takasaki Y
Nihon Jinzo Gakkai Shi; 2012; 54(5):598-602. PubMed ID: 22991839
[No Abstract] [Full Text] [Related]
11. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
Goldblatt F; Isenberg DA
Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
[TBL] [Abstract][Full Text] [Related]
12. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
13. B cell-ablative therapy for the treatment of autoimmune diseases.
Patel DD
Arthritis Rheum; 2002 Aug; 46(8):1984-5. PubMed ID: 12209499
[No Abstract] [Full Text] [Related]
14. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders.
Dierickx D; Delannoy A; Saja K; Verhoef G; Provan D
Am J Hematol; 2011 Mar; 86(3):278-91. PubMed ID: 21328427
[TBL] [Abstract][Full Text] [Related]
15. Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus.
Faria RM; Isenberg DA
Lupus; 2010 Sep; 19(10):1256-7. PubMed ID: 20534646
[No Abstract] [Full Text] [Related]
16. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
Tanaka Y
Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
[TBL] [Abstract][Full Text] [Related]
17. [Anti-CD20 antibody therapy for inflammatory immune diseases].
Tanaka Y
Nihon Naika Gakkai Zasshi; 2006 Sep; 95(9):1801-6. PubMed ID: 17037318
[No Abstract] [Full Text] [Related]
18. [B cells as key contributors in determining the level of immune responses -B-cell-targeted therapy in patients with autoimmune diseases].
Kondo S; Akashi T; Katsuta H; Iwakiri R; Anzai K; Nagafuchi S; Niho Y; Harada M
Fukuoka Igaku Zasshi; 2005 Apr; 96(4):86-92. PubMed ID: 15991605
[TBL] [Abstract][Full Text] [Related]
19. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
20. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases.
Kazkaz H; Isenberg D
Curr Opin Pharmacol; 2004 Aug; 4(4):398-402. PubMed ID: 15251135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
